Transaction gives BCI development and commercialization rights worldwide, except Japan and China.
BrainCells (BCI) in-licensed a development program from Taisho Pharmaceutical related to central nervous system (CNS) indications. Taisho retains rights to the program in Japan and China, while BrainCells will gain rights for the rest of the world.
The licensing agreement follows BCI’s determination that the program’s lead compound promotes neurogenesis. The company plans to complete preclinical development of this candidate, designated as BCI-632, and advance it into clinical trials.
“BCI will continue to build a pipeline of neurogenesis-promoting compounds through licensing agreements like this one,” comments Jim Schoeneck, BCI’s CEO. “We are pleased to have acquired rights to this Taisho program due to the unique receptor targets that are modulated by BCI-632 and the other compounds in this program. Through the use of our proprietary neurogenesis assay platform we have determined that the compounds we have licensed are highly neurogenic.”